Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2019 08:00 ET | Source: Nkarta

Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
November 18, 2019 17:16 ET | Source: Nkarta

Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
September 23, 2019 09:00 ET | Source: Nkarta

Nkarta Therapeutics Named as a “Fierce 15” Biotechnology Company of 2019

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
September 18, 2019 08:00 ET | Source: Nkarta

Nkarta Therapeutics Promotes Nadir Mahmood, Ph.D., to Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
September 10, 2019 08:00 ET | Source: Nkarta

Nkarta Therapeutics Appoints Vice President of Regulatory Affairs

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
September 04, 2019 08:00 ET | Source: Nkarta

Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
April 01, 2019 16:00 ET | Source: Nkarta

Nkarta Therapeutics Presents Data at AACR Demonstrating Proprietary NK Cell Engineering and Expansion Technology Enhances Potency and Cytotoxicity of NK Cells

SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing engineered Natural Killer (NK) cell therapies to fight cancer,...
December 10, 2018 08:00 ET | Source: Nkarta

Nkarta Therapeutics Announces Appointment of Matthew Plunkett, Ph.D., as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing engineered Natural Killer (NK) immune cells to fight cancer,...
November 27, 2018 08:00 ET | Source: Nkarta

Nkarta Therapeutics Appoints Kanya Rajangam, M.D., Ph.D, as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
November 09, 2018 08:00 ET | Source: Nkarta

Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model

NK cell potency and persistence significantly improved using cell engineering technology60% increase in cytotoxicity observed with Nkarta NK cells relative to control NK cellsSingle in vivo...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right